Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)
    Meeting Abstract

    Voss, M. H.; Coates, A.; Garmey, E. G.; Haas, N. B.; Hutson, T.; Keefe, S. M.; Motzer, R.; Piscitelli, A.; Vogelzang, N. J.; Figlin, R. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC)
    Meeting Abstract

    Nadal, R.; Amin, A.; Geynisman, D. M.; Voss, M. H.; Weinstock, M.; Doyle, J.; Zhang, Z.; Viudez, A.; Plimack, E. R.; McDermott, D. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3
    Meeting Abstract

    Hsieh, J.; Chen, D.; Wang, P.; Chen, Y. B.; Redzematovic, A.; Marker, M.; Patel, P.; Chevinsky, M.; Bhanot, U.; Pinciroli, P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D. F.; Ernstoff, M.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A. R. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prognostic value of genomic signatures in metastatic clear cell renal cell carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data
    Meeting Abstract

    de Velasco, G.; Fay, A. P.; Culhane, A.; Hakimi, A. A.; Voss, M. H.; Tannir, N. M.; Tamboli, P.; Appleman, L. J.; Bellmunt, J.; Rathmell, K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer
    Meeting Abstract

    Voss, M. H.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Woo, K.; Patil, S.; Molina, A. M.; Hsieh, J.; Motzer, R. J.; Feldman, D. R.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Pappas, K. M.; Wilson, D.; Zhang, X. S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs
    Meeting Abstract

    Lee, C. H.; Hoetker, A. M.; Voss, M. H.; Feldman, D. R.; Woo, K.; Patil, S.; Coskey, D. T.; Akin, O.; Hsieh, J.; Motzer, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation
    Meeting Abstract

    Kaffenberger, S. D.; Ciriello, G.; Winer, A. G.; Voss, M. H.; Maranchie, J. K.; Tamboli, P.; Rathmell, K.; Choueiri, T. K.; Motzer, R. J.; Coleman, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save